ABT-869 is an ATP-competitive, multi-targeted RTK inhibitor that is completely effective against all members of the vascular endothelial growth factor (Flt/Flk) and PDGFR families (e.g., Flk-1 (KDR), Flt-1, Flt-3/Flk-2, Flt-4, c-Fms-CSF-1R, and c-KIT) demonstrating IC50 values ranging from 4-190 nM. ABT-869 shows little activity against unrelated RTKs, cytoplasmic tyrosine kinases, or Ser/Thr kinases (IC50 > 1 μM). ABT-869 inhibits proliferation in MV-4-11 and MOLM-13 cells (acute myeloid leukemia cell lines harboring RTK mutations; IC50 = 4 and 6 nM, respectively), inducing apoptosis as evidenced by an increased sub-G0/G1 phase cell population, caspase activation, and PARP cleavage. In murine xenograft models, as well as in a phase 1 clinical trial, ABT-869 demonstrated respectable efficacy in solid tumors including lung and hepatocellular carcinomas.
1. Albert, D.H. et al. 2006. Mol. Cancer Ther. 5(4): 995-1006. PMID: 16648571
2. Shankar, D.B. et al. 2007. Blood. 109(8): 3400-3408. PMID: 17209055
3. Zhou, J. et al. 2009. J Hematol Oncol. 2 : 33. PMID: 19642998